

26. Diabetes Beyond Blood Glucose: The Microvascular and Tissue-Repair Dimensions

Absurd Health Institute | Medical Concept Papers, Volume Four | VI. From mechanism to disease

Publication type: Revised medical concept and hypothesis essay — not peer reviewed **Corrective edition:** 17 October 2026 **Substantive text:** 1,204 words

Abstract

Glucose exposure matters greatly in diabetes, but organ complications also involve microvascular injury, neural dysfunction, inflammatory signaling and structural remodeling. The paper asks how better glycemic measures and tissue-directed assessments can be interpreted together without minimizing the benefits of established glucose and risk-factor control.

Glucose exposure matters greatly in diabetes, but organ complications also involve microvascular injury, neural dysfunction, inflammatory signaling and structural remodeling. The paper asks how better glycemic measures and tissue-directed assessments can be interpreted together without minimizing the benefits of established glucose and risk-factor control.

The disease is more than one number

HbA1c is clinically valuable because chronic hyperglycemia contributes to long-term complications. But glucose measurement does not directly image retinal capillaries, renal glomerular architecture, peripheral nerve injury or local wound oxygenation. People with similar average glucose may differ in disease duration, blood pressure, lipoprotein exposure, susceptibility and cumulative tissue damage. These differences help explain why the complication burden is not identical across patients.

Microvasculature as a mediator

Diabetic retinopathy, nephropathy and neuropathy involve tissue-specific injury that may include endothelial dysfunction, basement membrane alterations, impaired perfusion and inflammation. In wounds, perfusion, neuropathy, immune defense and mechanical pressure can interact. These are mechanistic layers between metabolic exposure and clinical disability—not arguments that blood glucose is irrelevant.

Time creates lag

An improved metabolic state may reduce the rate of future injury yet leave existing fibrosis, nephron loss or axonal injury in place. Therefore short-term biochemical success and long-term tissue recovery should be measured separately. A person may feel little immediate change while reducing future complication risk, which is a powerful reason not to disparage established treatment because symptoms persist.

The proposed integrated assessment

We propose using disease-specific measures of tissue function alongside standard metabolic and cardiovascular measures, rather than replacing one with the other. Examples include retinal examinations, kidney function and albuminuria assessment, neurological examinations, vascular evaluations and foot-risk assessments when indicated. These tools already exist; the novelty would be a more explicit narrative linking them to states of injury and repair.

Alternative explanations

Not every complication in a person with diabetes is caused by diabetes. Inherited neuropathies, vascular occlusions, medications and other conditions may mimic diabetic complications. Conversely, vascular risk in diabetes is often influenced by blood pressure, smoking and apoB-containing lipoproteins. A whole-system model must retain these discriminations rather than claiming a single metabolic-bile-vascular cascade.

Clinical boundary

Lifestyle or fasting interventions cannot be portrayed as safe substitutes for indicated insulin or other treatments. Sudden medication changes can cause severe hypo- or hyperglycemia and ketoacidosis. The essential insight is that glycemic control is necessary to understand but may not fully describe the trajectory of tissue injury.

Vascular injury persists on a different clock

Glucose fluctuations, blood pressure exposure and lipoprotein-associated vascular risk act over months and years. Retinal microaneurysms, nerve damage or glomerular structural injury can retain a history of those exposures. Better contemporary numbers may lower progression risk even if anatomy does not immediately normalize. This difference should shape patient expectations and scientific reporting: prevention of further harm is a clinically major benefit, not evidence of incomplete or superficial medicine.

Why 'reversing diabetes' requires careful language

Remission of type 2 diabetes can be defined using specified glycemic criteria without glucose-lowering drugs, but remission of hyperglycemia does not erase all accumulated complication risk or guarantee permanent normal insulin physiology. Type 1 diabetes has an entirely different insulin-deficiency mechanism. A volume concerning tissue repair should not use the phrase 'diabetes reversal' without specifying disease type, metabolic state, complications and the time frame of observation.

A research question worth pursuing

Which tissue markers predict remaining risk after glycemic improvement, and which mechanisms are modifiable? This could involve retinal changes, albuminuria, renal function, vascular stiffness, neuropathic deficits or wound healing. The hypothesis is not that these should replace established markers, but that integrating structural and functional measures can improve the precision of recovery claims.

Glucose is a major driver, but not the whole phenotype

Diabetes is defined and managed through metabolic abnormalities involving glucose regulation, yet its complications include nerve injury, kidney dysfunction, retinal microvascular disease, cardiovascular damage and altered wound healing. Chronic exposure to elevated glucose contributes to several of these processes, interacting with blood pressure, lipoproteins, inflammation, renal function and genetic susceptibility. It would be wrong to treat vascular and repair biology as alternative explanations that make glycemic control optional. The more precise thesis is that some damage may persist even when glucose control improves, and that different patients have different degrees of recoverable tissue reserve.

A retinal example is especially clear. A person may achieve better glucose levels while existing retinal capillary damage requires continued surveillance and disease-specific treatment. In the kidney, albuminuria, filtration changes and structural alterations can have trajectories that are not perfectly synchronized with short-term glucose measurements. In the foot, perfusion, protective sensation, infection, pressure distribution and tissue integrity jointly determine ulcer risk. Treating these outcomes as one undifferentiated metabolic symptom loses important causal information.

The microvascular-repair intersection

Endothelial dysfunction, altered capillary recruitment and changes in extracellular matrix may contribute to poor nutrient delivery and impaired local healing in selected diabetic tissues. Hyperglycemia can affect immune-cell function and tissue repair, while peripheral neuropathy changes mechanical exposure and warning sensation. These mechanisms interact: an ulcer may arise because a patient cannot sense repeated pressure, then heal poorly because of infection and vascular compromise. Focusing exclusively on blood sugar misses the immediate mechanical and infectious factors, but ignoring glycemic disease would also be clinically unsound.

Claims of 'diabetes reversal' need similarly careful wording. Some people with type 2 diabetes achieve remission under accepted clinical definitions, but remission does not demonstrate erasure of all prior organ damage, and continued monitoring remains important. Type 1 diabetes requires a different physiological and therapeutic framework, including essential insulin replacement. A terrain paper must preserve these distinctions.

How to evaluate broader recovery

A thoughtful longitudinal study could follow patients after substantial glycemic improvement and separately evaluate retinal findings, renal function, neuropathy, wound healing and cardiovascular outcomes. The central hypothesis would be that baseline tissue injury and microvascular reserve modify the functional benefit of improved metabolism. Measurements must account for concurrent blood-pressure treatment, lipid-lowering therapy, weight change, medication effects and duration of disease.

Such research would be useful even if the primary result confirmed the enduring importance of glucose control. It might identify which residual abnormalities need additional evidence-based care and which patients recover function most readily. The clinically defensible conclusion is that metabolic improvement and tissue restoration are related but distinct achievements, both worth measuring without exaggerating either.

Remission and complication reversal are separate outcomes

A person with type 2 diabetes can enter sustained remission by accepted glycemic criteria and still require monitoring for cardiovascular, renal, retinal or neuropathic complications. The biological history of prolonged hyperglycemia may leave structural consequences whose recovery depends on the tissue. Conversely, improved glucose regulation can prevent progression and reduce future risk even when existing damage does not disappear. This makes remission a valuable metabolic achievement without making it synonymous with restored organ anatomy.

A particularly important comparison would follow patients with similar current HbA1c but different previous glycemic exposure and complication burden. If the groups differ in tissue outcomes, those differences may reflect cumulative injury, duration of disease, blood pressure, genetics or other factors rather than a mysterious independent toxin. Such analyses could help explain residual risk and identify targeted care. They would also prevent the false assumption that normal current blood glucose eliminates the need for established screening and preventive treatment.

Selected scientific reading

1. Reitsma S et al. The endothelial glycocalyx: composition, functions, and visualization. *Pflugers Arch*. 2007.
2. Østergaard L et al. Microcirculatory dysfunction and tissue oxygenation in critical illness. *Acta Anaesthesiol Scand*. 2015;59:1246–1259.
3. Liu F et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. *Am J Physiol Lung Cell Mol Physiol*. 2015.

Editorial and evidentiary note

This is an expanded conceptual synthesis, not original clinical research or a clinical treatment protocol. It preserves selected references from the original edition, whose bibliographic metadata have not all been independently reverified. Claims about specific diagnoses and treatments require appropriate primary evidence and professional assessment. Mechanistic plausibility does not establish therapeutic efficacy.